NASH
Clinical trials for NASH explained in plain language.
Never miss a new study
Get alerted when new NASH trials appear
Sign up with your email to follow new studies for NASH, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill aims to shrink liver fat in NASH patients
Disease control Recruiting nowThis study tests a new tablet called CS060380 for people with non-alcoholic steatohepatitis (NASH), a serious liver condition. About 120 adults will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track any side ef…
Matched conditions: NASH
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Could a common heart drug be the key to reversing fatty liver disease?
Disease control Recruiting nowThis study tests if a low dose of digoxin, a drug currently used for heart conditions, can help people with NASH (a severe type of fatty liver disease). About 144 adults with NASH and liver scarring will take oral digoxin for a period. The goal is to see if the drug can reverse t…
Matched conditions: NASH
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
Can genes predict liver cancer in fatty liver patients?
Knowledge-focused Recruiting nowThis study looks at how certain genes increase the risk of liver cancer (hepatocellular carcinoma) in people with nonalcoholic fatty liver disease (NAFLD). Researchers will follow 500 adults aged 45-75 with NAFLD to understand how genetic factors and lifestyle interact. The goal …
Matched conditions: NASH
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated May 26, 2026 03:09 UTC
-
New drug for fatty liver disease takes first step in human trials
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called BAR502 in 52 healthy adults aged 18-55. The drug is being developed for NASH, a serious liver condition. Participants receive either the drug or a placebo to check for side effects and how the body processes it.
Matched conditions: NASH
Phase: PHASE1 • Sponsor: BAR Pharmaceuticals s.r.l. • Aim: Knowledge-focused
Last updated May 26, 2026 03:06 UTC
-
Hormone link to fatty liver in young women under study
Knowledge-focused Recruiting nowThis study looks at how androgens (a type of sex hormone) might influence fatty liver disease in young women. Researchers will compare women with and without PCOS, a condition linked to high androgen levels and liver fat. The goal is to understand how liver health changes over ti…
Matched conditions: NASH
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 26, 2026 03:03 UTC